Ulixertinib in tumors with BRAF fusions, non-V600E or non-V600K BRAF mutations
Vivek Subbiah • 11 Apr 2022
Phase I/II trial of EP0031, a next generation selective RET inhibitor
Vivek Subbiah • 17 Apr 2023
Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter